Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (11-20 of 246) with videos related to

Pageof 25
Sort By:
Clinical Pharmacokinetics|August 24, 2007
Integrated pharmacokinetics and pharmacodynamics in drug developmentJasper Dingemanse, Silke Appel-Dingemanse
British Journal of Clinical Pharmacology|May 8, 2002
Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarinJasper Dingemanse, Carsten Meyerhoff, Jan Schadrack
Pharmacology|September 24, 2014
Single-dose pharmacokinetics of the renin inhibitor ACT-077825 in elderly and young subjects of both sexesJasper Dingemanse, Marzia Cavallaro, Urte Eydeler
Journal of Clinical Pharmacology|June 16, 2017
Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function ImpairmentNicolas Guérard, Christian Zwingelstein, Jasper Dingemanse
Pharmaceutics|October 11, 2016
Drug Development for Pediatric Populations: Regulatory AspectsJochen Zisowsky, Andreas Krause, Jasper Dingemanse
Clinical Pharmacokinetics|February 15, 2020
Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor AntagonistsUta Schilling, Jasper Dingemanse, Mike Ufer
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 7, 2021
Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjectsBenjamin Berger, Rüdiger Kornberger, Jasper Dingemanse
Fundamental & Clinical Pharmacology|August 2, 2012
Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolamJasper Dingemanse, Laurent Nicolas, Christoph Binkert
Pulmonary Pharmacology & Therapeutics|March 5, 2018
Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertensionAndreas Krause, Jochen Zisowsky, Jasper Dingemanse
Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie|August 14, 2009
Phospholipidosis in healthy subjects participating in clinical studies: ultrastructural findings in white blood cellsAndreas Pospischil, Paul Walther, Jasper Dingemanse
Pageof 25

Showing results (11-20 of 246) with videos related to

Sort By:
Pageof 25
Clinical Pharmacokinetics|August 24, 2007
Integrated pharmacokinetics and pharmacodynamics in drug developmentJasper Dingemanse, Silke Appel-Dingemanse
British Journal of Clinical Pharmacology|May 8, 2002
Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarinJasper Dingemanse, Carsten Meyerhoff, Jan Schadrack
Pharmacology|September 24, 2014
Single-dose pharmacokinetics of the renin inhibitor ACT-077825 in elderly and young subjects of both sexesJasper Dingemanse, Marzia Cavallaro, Urte Eydeler
Journal of Clinical Pharmacology|June 16, 2017
Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function ImpairmentNicolas Guérard, Christian Zwingelstein, Jasper Dingemanse
Pharmaceutics|October 11, 2016
Drug Development for Pediatric Populations: Regulatory AspectsJochen Zisowsky, Andreas Krause, Jasper Dingemanse
Clinical Pharmacokinetics|February 15, 2020
Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor AntagonistsUta Schilling, Jasper Dingemanse, Mike Ufer
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 7, 2021
Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjectsBenjamin Berger, Rüdiger Kornberger, Jasper Dingemanse
Fundamental & Clinical Pharmacology|August 2, 2012
Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolamJasper Dingemanse, Laurent Nicolas, Christoph Binkert
Pulmonary Pharmacology & Therapeutics|March 5, 2018
Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertensionAndreas Krause, Jochen Zisowsky, Jasper Dingemanse
Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie|August 14, 2009
Phospholipidosis in healthy subjects participating in clinical studies: ultrastructural findings in white blood cellsAndreas Pospischil, Paul Walther, Jasper Dingemanse
Pageof 25